155 related articles for article (PubMed ID: 11106262)
1. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
[TBL] [Abstract][Full Text] [Related]
3. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
[TBL] [Abstract][Full Text] [Related]
4. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2004 Feb; 53(2):173-8. PubMed ID: 14605863
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer HA; Ouwehand M; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2004 Aug; 22(3):219-29. PubMed ID: 15122069
[TBL] [Abstract][Full Text] [Related]
8. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
9. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Drug Metab Dispos; 1999 Jul; 27(7):827-34. PubMed ID: 10383928
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
11. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
12. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
13. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
14. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
16. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
18. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
19. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA; Ouwehand M; Malingré MM; Schellens J; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
[TBL] [Abstract][Full Text] [Related]
20. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]